Progenra plans to radically change the therapeutic landscape by uncovering first in class, novel therapies from the ubiquitin proteasome system. Progenra has been working to create a knowledge base and patent technology designed to understand and explore the intricacies of the ubiquitin proteasome system and to employ these tools to discover small molecules that modulate the function of key system enzymes for therapeutic benefit. Progenra scientists have discovered small molecule preclinical development candidates for the treatment of cancer (via both direct tumoricidal and immunological mechanisms), inflammatory diseases, and neurodegeneration. An additional outcome of these programs is the identification of small molecule ubiquitin proteasome system modulators, such as the pan-DUB inhibitor PR-619, that have contributed enormously to chemical biology studies of ubiquitin signaling and are employed universally today along with proteasome inhibitors in translational studies. Progenra can provide these assets to any partner with a similar interest; we firmly believe that by combining resources and know-how we can improve a program’s chance of success.
Progenra is seeking industry partnerships for licensing opportunities surrounding the company's small molecule portfolio and/or its proprietary UbiPro™ Drug Discovery Platform.